Overcoming Barriers to Access in Cell and Gene Therapy | Asembia’s AXS25 Summit
April 29th 2025Joe DePinto from McKesson discussed the challenges facing cell and gene therapies, particularly around reimbursement, and highlighted successful strategies to speed up access. He also shared optimism for the future, with many products already achieving blockbuster status and more expected by 2030.
Watch
Are Cell and Gene Therapies Overpromised or Facing Growing Pains | Asembia's AXS25 Summit
April 29th 2025Joe DePinto, MBA, head of cell, gene and advanced therapies at McKesson , met with MHE at the annual Asembia Specialty Pharmacy Summit in Las Vegas this week to give some insight on where we are with cell and gene therapies, as well as looking at Pfizer's discontinued hemophilia B gene therapy, Beqvez (fidanacogene elaparvovec-dzkt).
Watch
AI is a Physician Complement, Not Replacement, Expert Says | Asembia's AXS25 Summit
April 29th 2025As healthcare AI evolves, there will be a greater emphasis on streamlining administrative tasks, drug production and service delivery, according to George Van Antwerp, SVP of product innovation and strategic planning at Prime Therapeutics.
Watch
Luke Greenwalt, MBA, on the Current Market Conditions for New Drug Launches | Asembia's AXS25 Summit
April 28th 2025The vice president and lead of IQVIA's Market Access Center of Excellence says fewer drugs are hitting the $100 million mark during their first year on the market than in the past.
Watch
Preserving Beta Cell Function in T1D: Current Strategies and Emerging Therapies
April 25th 2025A panelist discusses how preserving beta-cell function in type 1 diabetes (T1D) requires a multifaceted approach combining timely diagnosis, immunomodulatory therapies, optimal glycemic control and emerging technologies that can slow disease progression and improve patient outcomes.
Watch
Important Takeaways Regarding the Utilization of Ruxolitinib
April 21st 2025Panelists discuss how ruxolitinib offers significant advantages in atopic dermatitis management through its targeted JAK inhibition mechanism, demonstrating rapid and sustained improvement in itch and lesions, effectiveness across various disease severities and body regions, favorable safety profile compared to systemic alternatives, and potential for reduced healthcare resource utilization over extended treatment periods.
Watch
Closing Insights: The Future of Cemiplimab in NSCLC and Beyond
April 18th 2025Panelists discuss how, as new data on cemiplimab and other checkpoint inhibitors emerge, the treatment pathway for cancers like non-small cell lung cancer (NSCLC) is expected to evolve toward more personalized, targeted approaches. This will enhance survival outcomes, refine patient selection and optimize therapy regimens.
Watch
Misdiagnosis of Type 1 Diabetes in Adults: Prevalence, Causes and Consequences
April 18th 2025A panelist discusses how type 1 diabetes (T1D) is frequently misdiagnosed in adults due to its overlapping clinical features with type 2 diabetes (T2D), resulting in inappropriate treatment strategies that fail to address the autoimmune destruction of beta cells and lead to accelerated disease progression and complications.
Watch
The Role of Continuing Cemiplimab in Second-Line Therapy After Progression
April 18th 2025Panelists discuss how, cemiplimab, a PD-1 inhibitor, has shown promise as a second-line therapy for advanced NSCLC after progression on prior treatments. Continuing cemiplimab post-progression can enhance survival outcomes by maintaining immune system activation against cancer cells.
Watch
Jennifer Haley Debunks the Belief That Medicaid Work Requirements Will Push Its Users to Work
April 16th 2025In this first part of a two-part video series, Jennifer Haley, principal research associate of the Health Policy Division at the Urban Institute, spoke with MHE about the impact the proposed Medicaid work requirements could have on millions and research that supports this belief.
Watch
Evaluating Ruxolitinib In An 18-Month Retrospective Claims Analysis
April 14th 2025Panelists discuss how an 18-month retrospective claims analysis evaluated ruxolitinib's real-world effectiveness in atopic dermatitis, demonstrating sustained disease control, reduced healthcare utilization, decreased steroid dependency, improved medication adherence, and consistent safety outcomes across diverse patient demographics and disease severities compared to conventional treatments.
Watch
Managing Safety and Quality of Life With Cemiplimab in Advanced NSCLC
April 11th 2025Panelists discuss how balancing survival benefits with quality of life involves careful monitoring of treatment-related adverse effects. Managing immune-related adverse events in patients on immune checkpoint inhibitors like cemiplimab requires early detection, timely intervention and proactive strategies to minimize impact on outcomes.
Watch
Subgroup Analyses of EMPOWER-LUNG 1
April 11th 2025Panelists discuss how subgroup analyses of the EMPOWER-Lung 1 study assessed the efficacy of pembrolizumab across various patient groups, including those with different PD-L1 expression levels, tumor histology and prior therapies. Results demonstrated consistent survival benefits, highlighting pembrolizumab’s broad clinical applicability in advanced non-small cell lung cancer (NSCLC).
Watch
Advancing Early Detection: Autoimmune Screening in Type 1 Diabetes
April 11th 2025A panelist discusses how autoimmune screening through detection of diabetes-specific autoantibodies serves as a critical tool for identifying pre-symptomatic type 1 diabetes (T1D), enabling earlier intervention before significant beta cell loss occurs and potentially changing the disease trajectory through timely management strategies.
Watch
Chronic Itch Often Overlooked as New Treatments Face Coverage Hurdles
April 10th 2025In this second part of a video series, Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, described a common scenario where patients with severe atopic dermatitis must first try and fail multiple topical treatments, all while having widespread symptoms, before insurers will approve systemic therapies.
Watch
Pharmaceutical Market Trend Insight, Experts Talk GLP-1 Competition and More | AMCP Annual 2025
April 10th 2025Current observations and foresight into the world of biosimilars, GLP-1s, PBM and payer trends, according to Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, and Doug Long, MBA, vice president of industry relations at IQVIA.
Watch
The Future of Pulmonary Fibrosis Management: Precision Medicine, Biomarkers and AI
April 10th 2025Eric Cannon, PharmD, FAMCP, discusses how precision medicine advancements and biomarker development can enable targeted idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) therapies by identifying patient subgroups most likely to benefit from specific interventions. Artificial intelligence (AI) integration offers potential for earlier diagnosis, improved prognostication and personalized treatment optimization through data pattern recognition.
Watch